THU0104 Both MRI and HAQ-DI can predict relapses following all treatment withdrawal in MTX-NAÏVE patients with RA in remission after 12 months of abatacept therapy in the avert trial

Abstract

BackgroundFactors predictive of relapse need to be identified to aid therapy withdrawal decisions for patients with RA achieving remission with treatment. AVERT (NCT01142726) was a Phase IIIb, randomized, active-controlled trial...